药品
曲妥珠单抗
指南
免疫分析
医学
抗体
药理学
免疫学
内科学
癌症
病理
乳腺癌
作者
Nidhi Nath,Becky Godat,Rod Flemming,Marjeta Urh
出处
期刊:Methods in molecular biology
日期:2021-09-04
卷期号:: 313-322
标识
DOI:10.1007/978-1-0716-1450-1_20
摘要
Any immune reaction to therapeutic antibodies will impact the drug efficacy and can have serious consequences for patient safety. Therefore, detection and reporting of anti-drug antibodies (ADA) during clinical trials is required by regulatory agencies during drug approval process. We have developed a bioluminescent bridging immunoassay for ADA detection, which uses an extremely bright NanoLuc enzyme as a reporter. The assay is sensitive with a wide dynamic range and meets the FDA drug tolerance guideline of detecting 100 ng/ml of ADA in the presence of 500-fold excess of free drug. We describe detailed protocols for development of ADA assays using therapeutic Trastuzumab as a model drug and an anti-Trastuzumab antibody as an example of immune response.
科研通智能强力驱动
Strongly Powered by AbleSci AI